Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)
A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)

NCT06384547

CompletedPhase 3

Sponsor: Viridian Therapeutics, Inc.

Conditions: Thyroid Eye Disease

Interventions: Veligrotug

Countries: United States, Australia, France, Germany, Poland, Spain, United Kingdom

The investigational drug, VRDN-001, is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R). Inhibition of IGF-1R may help to reduce the inflammation and associated tissue swelling that occurs in participants with TED. The primary objective of this clinical trial is to evaluate the safety and tolerability of VRDN-001 in participants with TED.

Eligibility overview

Sex: ALL

Age: 18 Years to 75 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Have a clinical diagnosis of TED with or without proptosis and with any clinical activity score (CAS) (0 - 7) and in the opinion of the investigator may benefit from treatment
* Must agree to use highly effective contraception method as specified in the protocol
* Female TED participants must have a negative serum pregnancy test at screening
* Not require immediate ophthalmological or orbital surgery in the study eye for any reason.

Exclusion Criteria:

* Must not have received prior treatment with another anti-IGF-1R therapy
* Must not have used systemic corticosteroids, or selenium within 2 weeks prior to Day 1
* Must not have received rituximab, tocilizumab or other immunosuppressive agents within 8 weeks prior to Day 1
* Must not have received any other therapy for TED within 8 weeks prior to Day 1
* Must not have received an investigational agent for any condition within 8 weeks prior to the first dose of study medication
* Must not have a pre-existing ophthalmic condition in the study eye that in the opinion of the Investigator would confound interpretation of the study results
* Must not have had previous orbital irradiation or decompression surgery involving excision of fat for TED in the study eye's orbit
* Must not have inflammatory bowel disease
* Must not have abnormal hearing test before first dose. Must also not have a history of ear conditions considered significant by study doctor.
* Female TED participants must not be pregnant or lactating.
Locations (50)
  • Inglewood, California, United States
  • Los Angeles, California, United States
  • Palo Alto, California, United States
  • San Diego, California, United States
  • Santa Maria, California, United States
  • Aurora, Colorado, United States
  • Homestead, Florida, United States
  • Miami, Florida, United States
  • Plantation, Florida, United States
  • Sarasota, Florida, United States
  • Orland Park, Illinois, United States
  • Kansas City, Kansas, United States
  • Kansas City, Kansas, United States
  • Boston, Massachusetts, United States
  • Weymouth, Massachusetts, United States
  • Fraser, Michigan, United States
  • Livonia, Michigan, United States
  • Minneapolis, Minnesota, United States
  • Las Vegas, Nevada, United States
  • Newark, New Jersey, United States
  • New York, New York, United States
  • Houston, Texas, United States
  • Houston, Texas, United States
  • Houston, Texas, United States
  • Burlington, Vermont, United States
  • Morgantown, West Virginia, United States
  • Sydney, Australia
  • Sydney, Australia
  • Angers, France
  • Des Quinze Vingts Paris, France
  • + 20 more on CT.gov